{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-060828","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.379405+00:00","generated_at":"2026-06-18T11:52:31.836858+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio reports positive Phase 2 Cohort 5 data for infigratinib in achondroplasia; mean AHV increase +3.03 cm/yr","bullets":["Mean change from baseline in annualized height velocity (AHV) at six months: +3.03 cm/yr (p=0.0022) in Cohort 5 (0.25 mg/kg daily).","80% of 10 children with six-month visits were responders (≥25% increase in AHV); mean change among responders +3.81 cm/yr.","No treatment-related adverse events in Cohort 5; no SAEs or discontinuations in any cohort.","BridgeBio has started enrolling children in a Phase 3 trial and plans to initiate development for hypochondroplasia.","Median absolute AHV reached 7.6 cm/yr, beyond the 99th percentile for achondroplasia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-060828","json":"https://secwatch.observer/filing/0001193125-23-060828.json","markdown":"https://secwatch.observer/filing/0001193125-23-060828.md","text":"https://secwatch.observer/filing/0001193125-23-060828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523060828/0001193125-23-060828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523060828/d467337d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:52:31.836858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}